Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Villejuif – page 130

3 340 clinical trials in Villejuif, France across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Villejuif at a glance
3 340
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

3 340 trials in Villejuif

Open in trial search

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glatiramer Acetate
  • Sponsor:Torl Biotherapeutics LLC

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Giant cell arteritis

Not yet recruiting

Study of bosentan, prednisone and prednisolone in patients with newly diagnosed or relapsing giant cell arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Chondrocalcinosis

Not yet recruiting

Study of tocilizumab compared to placebo in patients with chronic chondrocalcinosis who did not respond to standard treatments

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Assistance Publique Hopitaux De Paris

Parkinson's disease+1

Not yet recruiting

Study of serotonin system changes in early Parkinson's disease using [11C]DASB and [11C]SB207145 PET imaging in people with SNCA gene mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:DASB C-11
  • Sponsor:Institut National De La Sante Et De La Recherche Medicale

Malignant melanoma

Not yet recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with Metastatic Melanoma

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Neovascular age-related macular degeneration

Not yet recruiting

Long-term Safety and Effectiveness Evaluation of RGX-314 in Patients with Neovascular Age-related Macular Degeneration

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Surabgene lomparvovec
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Neoplasm

Not yet recruiting

Study of Valemetostat Tosylate with Drug Combination for Patients with Previously Treated Solid Tumors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Datopotamab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Gastrointestinal disorder

Not yet recruiting

Study on the Safety and Effects of Orziloben (NST-6179) for Patients with Intestinal Failure-Associated Liver Disease

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Orziloben
  • Sponsor:NorthSea Therapeutics B.V.

Acute myocardial infarction

Not yet recruiting

Study on Methoxyflurane for Pain Relief in Patients with Heart Attack

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Methoxyflurane 99.9%
  • Sponsor:Assistance Publique Hopitaux De Paris

Coronavirus infection

Not yet recruiting

Study on the Safety and Immune Response of OVX033 Vaccine for Adults with Sarbecovirus Disease

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:OVX033
  • Sponsor:Osivax

Gastroenteropancreatic neuroendocrine tumour disease+5

Not yet recruiting

Study on the Safety and Effectiveness of Domvanalimab and Zimberelimab for Adults with Advanced Rare Cancers Resistant to Standard Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Domvanalimab
  • Sponsor:Hospices Civils De Lyon

Other cities in France

The busiest research cities in the country

All 366 cities in France

Clinical research in Villejuif

What the registry says about research in the country

01 Oncology - Head and Neck Cancer

Innovative research focusing on locally advanced head and neck squamous cell carcinoma treatments, including novel therapies combined with radiotherapy and immunotherapy approaches.

  • NBTXR3 with radiotherapy
  • EGFR-ADC therapy combinations
  • HPV-positive oropharyngeal cancer
02 Gastrointestinal Oncology

Studies targeting various digestive system cancers, with particular focus on pancreatic adenocarcinoma and advanced gastric cancer treatments.

  • Anti-CEACAM5 ADC therapy
  • Sotorasib combinations
  • Novel gastrointestinal cancer treatments
03 Hematologic Malignancies

Cutting-edge research in multiple myeloma treatment, exploring new combination therapies and maintenance approaches.

  • Elranatamab-lenalidomide therapy
  • Belantamab mafodotin combinations
  • T-cell lymphoma treatments
04 Lung Cancer Research

Comprehensive studies in both non-small cell lung cancer and small cell lung cancer, investigating targeted therapies and immunotherapy combinations.

  • Novel antibody-drug conjugates
  • Microbiome-based approaches
  • Targeted therapy combinations
05 Advanced Solid Tumors

Broad-spectrum research investigating novel treatments for metastatic solid tumors, including innovative therapeutic approaches and combination strategies.

  • PARG inhibitor studies
  • Targeted molecular therapies
  • Immunotherapy combinations
Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.